EBSAM
NVS icon

Eubel Brady & Suttman Asset Management’s Novartis NVS Stock Holding History

Eubel Brady & Suttman Asset Management’s Portfolio NVS Stock Details NVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-51
Closed -$4K – 253
2021
Q2 		$4K Buy
+51
New +$4.54K ﹤0.01% 574

Other funds holding NVS

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Aristotle Capital Management
Aristotle Capital Management Los Angeles, California $47.8B AUM 13.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Eubel Brady & Suttman Asset Management's NVS Position: Q3 2021 in Review

Eubel Brady & Suttman Asset Management sold out of Novartis (NVS) in Q3 2021, closing a stake of 51 shares — an estimated $4K sold.

Eubel Brady & Suttman Asset Management first reported a position in NVS in Q2 2021 and held it in 1 quarter. The position peaked at $4K in Q2 2021. 1,080 funds tracked by Wall St. Rank hold NVS as of Q3 2021.

  • Eubel Brady & Suttman Asset Management reported no remaining Novartis position as of Q3 2021 after selling out during the quarter.
  • Eubel Brady & Suttman Asset Management sold 51 Novartis shares in Q3 2021, an estimated $4K.
  • Eubel Brady & Suttman Asset Management first reported a position in Novartis in Q2 2021 and held it in 1 quarter.
  • Eubel Brady & Suttman Asset Management's Novartis position peaked at $4K in Q2 2021.
  • 1,080 funds tracked by Wall St. Rank held Novartis as of Q3 2021.

Based on Eubel Brady & Suttman Asset Management's 13F filing for Q3 2021, filed 5 Nov 2021.